Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	КҮ	MD	NJ	NV	NY	TN	TX	WA
Applicable	Χ	Х	NA	NA	Х	NA	Χ	Х	Χ	Χ	Χ	NA	NA	X

^{*}FHK- Florida Healthy Kids

Zolendronic Acid

CG-DRUG-41

Override(s)	Approval Duration
Prior Authorization	1 year
Quantity Limit	

Medications	Quantity Limit						
Reclast (zoledronic acid)	100 mL (5mg) once per year						
Zometa (zoledronic acid)	N/A						

APPROVAL CRITERIA

Requests for zoledronic acid (Reclast, Zometa) may be approved for any of the following conditions:

- I. Bone metastases documented on imaging or bone pain associated with imaging-documented metastases from breast, prostate, lung, kidney, thyroid, or other solid tumors; **OR**
- II. Breast cancer, prevention of bone loss secondary to adjuvant hormone therapy (i.e. aromatase inhibitors); **OR**
- III. Breast cancer, early stage, premenopausal prevention of bone loss secondary to ovarian dysfunction induced by adjuvant chemotherapy therapy; **OR**
- IV. Glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who are expected to remain on glucocorticoids for at least 12 months; **OR**
- V. Hypercalcemia of malignancy, treatment; **OR**
- VI. Multiple myeloma; OR
- VII. Osteoporosis, treatment to increase bone mass in men; **OR**
- VIII. Osteoporosis, treatment and prevention in postmenopausal women; **OR**
- IX. Paget's disease of bone in men and women- treatment indicated with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the age-specific normal reference range, or those who are symptomatic, or those at risk for complications from their disease; **OR**
- X. Prevention of osteoporosis during androgen deprivation therapy in prostate cancer.

PAGE 1 of 2 07/17/2018

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	Χ	Х	NA	NA	Χ	NA	Х	Χ	Χ	Χ	Χ	NA	NA	Χ

^{*}FHK- Florida Healthy Kids

State Specific Mandates								
State name N/A	Date effective N/A	Mandate details (including specific bill if applicable) N/A						

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: http://www.clinicalpharmacology.com. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. http://dailymed.nlm.nih.gov/dailymed/about.cfm.

DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.

PAGE 2 of 2 07/17/2018

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0210-18